The biotech IPO train keeps chug­ging, as Virios prices $30M pub­lic de­but

Chest­nuts roast­ing on an open fire, biotechs keep pric­ing IPOs.

Virios Ther­a­peu­tics priced its pub­lic de­but on Thurs­day, bring­ing home $30 mil­lion and con­tribut­ing to this year’s record raise of near­ly $15 bil­lion. How­ev­er, the At­lanta-based biotech raised less than its ini­tial goal set in Au­gust, and much less than oth­er IPOs we’ve seen this year, many of which fea­tured up­sized of­fer­ings. Virios’ 3 mil­lion shares came in at $10 apiece, the mid­point of a $9 to $11 range.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER